Lexaria Bioscience (LEXX) Cash & Current Investments (2010 - 2026)

Lexaria Bioscience has reported Cash & Current Investments for 17 years, with the latest figure at $3.5 million in Q2 2026.

• Quarterly Cash & Current Investments fell 24.87% year-over-year to $3.5 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $3.5 million (down 24.87% YoY) and the FY2025 annual result came in at $1.8 million, down 71.93% from the prior year.
• Cash & Current Investments eased to $3.5 million in Q2 2026 per LEXX's latest filing, from $5.1 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $8.9 million in Q1 2022 and troughed at $1.5 million in Q3 2023.
• A 5-year average of $5.1 million and a median of $4.8 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments plunged 76.01% in 2023, then surged 339.85% in 2024.
• Over 5 years, Cash & Current Investments stood at $4.8 million in 2022, then plunged by 57.8% to $2.0 million in 2023, then soared by 300.58% to $8.1 million in 2024, then sank by 45.5% to $4.4 million in 2025, then slipped by 21.46% to $3.5 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $3.5 million, $5.1 million, and $4.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.